At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer, infectious disease and orphan diseases.
INBRX-109, a multivalent antibody targeting DR5 in Phase 1 for multiple oncology indications. Explore →INBRX-105, a multispecific/multivalent antibody targeting PDL1 and 41BB for multiple oncology indications aiming to enter the clinic in January of 2019. Explore →INBRX-101, an optimized fusion protein for Alpha-1 Disease expected to enter the clinic in 1H 2019. Explore →INBRX-103, a differentiated anti-CD47 mAb in a Phase 1 trial in combination with rituximab. Licensed by Celgene. Explore →